Long-Term Safety and Effectiveness of Adalimumab for Moderat-to-Severe Psoriasis: Results from the Eight-Year Interim Analysis of the ESPIRIT Registry. J of Skin 2017, 1 (3.1), s22. https://doi.org/10.25251/skin.1.supp.21.